[1] MILOJKOVIC D,LYON AR,MEHTA P,et al.Cardiovascular risk in chronic myeloid leukaemia:A multidisciplinary consensus on screening and management[J].Eur J Haematol,2023,111(2):201-210.
[2] TUSA I,CHELONI G,POTETI M,et al.In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features[J].Target Oncol,2020,15(5):659-671.
[3] CIAFFAGLIONE V,CONSOLI V,INTAGLIATA S,et al.Novel tyrosine kinase inhibitors to target chronic myeloid leukemia[J].Molecules,2022,27(10):3220.
[4] HOLYOAKE TL,VETRIE D.The chronic myeloid leukemia stem cell:stemming the tide of persistence[J].Blood,2017,129(12):1595-1606.
[5] RADICH JP,HOCHHAUS A,MASSZI T,et al.Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia:5-year update of the ENESTfreedom trial[J].Leukemia,2021,35(5):1344-1355.
[6] TUSA I,CHELONI G,POTETI M,et al.Targeting the extracellular signal-regulated kinase 5 pathway to suppress human chronic myeloid leukemia stem cells[J].Stem Cell Reports,2018,11(4):929-943.
[7] KANTARJIAN HM,HUGHES TP,LARSON RA,et al.Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase:ENESTnd 10-year analysis[J].Leukemia,2021,35(2):440-453.
[8] 王信,马传江,杨培民,等.白花蛇舌草抗炎、抗肿瘤作用研究进展[J].中国现代应用药学,2020,37(19):2420-2427.
WANG X,MA CJ,YANG PM,et al.Research progress of anti-inflammatory and anti-tumor effects of hedyotis diffusa willd [J].Chinese Journal of Modern Applied Pharmacy,2020,37(19):2420-2427.
[9] 陈筱凡.白花蛇舌草提取物体外抑制K562细胞增殖实验研究[J].浙江中西医结合杂志,2013,23(1):14-17.
CHEN XF.Hedyotis herb extracts inhibited the proliferation of human leukemia cell line K562 in vitro [J].Zhejiang Journal of Integrated Traditional Chinese and Western Medicine,2013,23(1):14-17.
[10] 吴逢选,周郁鸿,叶宝东.白花蛇舌草抗肿瘤机制研究进展及其在血液病中的应用[J].中华中医药杂志,2015,30(1):167-169.
WU FX,ZHOU YH,YE BD.Research progress on anti-tumor effect and mechanisms of hedyotis diffusa willd and its application in blood disease [J].China Journal of Traditional Chinese Medicine and Pharmacy,2015,30(1):167-169.
[11] YI Z,WANG Z,LI H,et al.Inhibitory effect of tellimagrandin I on chemically induced differentiation of human leukemia K562 cells[J].Toxicol Lett,2004,147(2):109-119.
[12] OKABE S,GOTOH A.Effect of asciminib and vitamin K2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells[J].BMC Cancer,2023,23(1):827.
[13] MINASSIAN LM,COTECHINI T,HUITEMA E,et al.Hypoxia-induced resistance to chemotherapy in cancer[J].Adv Exp Med Biol,2019,1136:123-139.
[14] ZHANG F,LIU Z,HE X,et al.β-Sitosterol-loaded solid lipid nanoparticles ameliorate complete Freund's adjuvant-induced arthritis in rats:involvement of NF-кB and HO-1/Nrf-2 pathway[J].Drug Deliv,2020,27(1):1329-1341.
[15] SMUKOWSKA-GORYNIA A,RZYMSKI P,MARCINKOWSKA J,et al.Prognostic value of oxidative stress markers in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension[J].Oxid Med Cell Longev,2019,2019:3795320.
[16] TRCK P,FRAGA S,SALVADOR I,et al.Blueberry extract decreases oxidative stress and improves functional parameters in lungs from rats with pulmonary arterial hypertension[J].Nutrition,2020,70:110579.
[17] 林兰明,宋征宇,胡瑾.金合欢素调节TLR4/NLRP3信号通路对脑缺血再灌注损伤模型大鼠的保护作用[J/OL].中国中药杂志[2023-09-11].https://kns.cnki.net/kcms/detail/11.2272.r.20230721.1722.002.html.DOI:10.19540/j.cnki.cjcmm.20230719.401.
LIN LM,SONG ZY,HU J.Acacetin protects rats from cerebral ischemia-reperfusion injury by regulating TLR4/NLRP3 signaling pathway[J/OL].China Journal of Chinese Materia Medica[2023-09-11].https://kns.cnki.net/kcms/detail/11.2272.r.20230721.1722.002.html.DOI:10.19540/j.cnki.cjcmm.20230719.401.
[18] 丁碧莹,王学锋.GATA结合蛋白1的造血调控功能及其突变导致的红系/巨核系相关遗传病[J].中国输血杂志,2023,36(1):85-90.
DING BY,WANG XF.Hematopoietic regulation of transcription factor GATA1 and mutations causing hereditary erythroid and megakaryocytic disorders[J].Chinese Journal of Blood Transfusion,2023,36(1):85-90.
[19] ZHANG C,GUO LY,MU D,et al.Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin[J].Oncol Rep,2019,41(1):475-482.